Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
This patient deals with type 2 diabetes and, later on, used Ozempic to achieve lowered A1C under 7% while losing some weight throughout the process
Employers only pay when predefined outcomes are achieved Guaranteed improvements in A1C, weight loss, and deprescription of GLP-1s and other medications ROI is validated using pharmacy and medical claims data Reported outcomes include a 2.2-point average A1C reduction for members with starting A1C greater than8.0 and a 14-pound average weight loss for members with a BMI greater than 30, based on internal data from Twin Healths commercial populations as of September 2024 Demonstrated reductions in diabetes-related pharmacy spend while maintaining clinical appropriateness Precision medication management Employers can start by using claims and clinical data to identify risk levels and guide GLP-1 eligibility
As part of the Medication & Lifestyle Program, health guides provide guidance on nutrition, physical activity, and overall wellness to complement your personalized treatment plan
Seeger JD, Nunes A, Loughlin AM
Science Despite the growing number of GLP-1 supplements on the market, the evidence supporting these products is limited at best
